Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of therapeutic effects of denosumab and romosozumab in postmenopausal osteoporosis using propensity score matching
jRCT1041200090Recruiting
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of denosumab and romosozumab in involutional osteoporosis and postmenopausal osteoporosis (2 arms), sponsored by none. Primary endpoint: Change in lumbar spine bone mineral density. Started Apr 2018; status: recruiting.
02
Drugs
denosumabromosozumab
03
Conditions
involutional osteoporosispostmenopausal osteoporosis
Beyond the preview
Go deeper on jRCT1041200090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041200090.